Cagrilintide is a long-acting amylin analog designed for research in weight management and metabolic regulation. It works by mimicking the natural amylin hormone to reduce food intake, slow gastric emptying, and extend the feeling of satiety, providing a powerful tool for studying appetite control and energy balance. The upgraded 10mg concentration delivers a higher active dose per vial, making it ideal for medium to high dose response studies, extended metabolic intervention protocols, and large-scale repeat experiments. With fewer dilution steps required, this specification improves dosing accuracy and reduces experimental error. When combined with incretin-based peptides such as semaglutide, Cagrilintide supports deeper research into complementary weight loss mechanisms and long-term glycemic stability. Its extended duration of action ensures consistent, reproducible results across prolonged study periods, while the high-purity lyophilized formulation maintains stable bioactivity for reliable data output in advanced metabolic research programs.